Categories
Crypto

MARKETS DAILY: Central Bank Digital Currencies and US Dollar Dominance in 2020

Adam B. Levine and Bradley Keoun
With 2019 vanishing in the rear view mirror, Markets Daily is back for an insightful look into Central Bank Digital Currencies (CBDCs) and the US Dollar’s ongoing reserve status.

Tune in as CoinDesk podcasts editor Adam B. Levine and senior markets reporter Brad Keoun run down recent action, track interesting longer-term trends, and highlight the best “thinking with tokens” and some of the most important crypto industry developments of the day.

No time to listen? Scroll down for the transcript with full links.

Having trouble with the embedded player? You can download the MP3 here.

In this episode:

  • Markets, international and industry news roundup
  • 2020 looks set to be a big year for Central Bank Digital Currencies (CBDCs), but why? Adam gets into it, with a look at the innovation vs. optimization mindsets
  • Another decade of US dollar reserve dominance? Brad’s dug into the numbers and shares his results

Transcript

Adam B. Levine: On Today’s episode, bitcoin in the new year, Bahamanian Blockchain Bucks and a look at US Dollar reserve status.

Adam: It’s January 2, 2020, and you’re listening to Markets Daily, I’m Adam B. Levine, editor of Podcasts here At Coindesk, along with our senior markets reporter, Brad Keoun, to give you a concise daily briefing on crypto markets and some of the most important news developments in the sector over the past 24 hours. 

Brad: Bitcoin currently around $7100, essentially in the range where it traded through most of the holidays in what was a very calm and quiet end to the year for the largest cryptocurrency, after some pretty wild market swings over the course of the past 12 months

And just to close the books on 2019, bitcoin prices rose $3,475 on the year, recovering roughly a third of the $10,186 decline we saw during 2018, which was so brutal on the entire crypto industry that it’s often referred to as “Crypto Winter”

Bitcoin’s full-year price rise works out to a 94 percent gain on the year, or almost double, in its best year since 2017, when the cryptocurrency’s price famously jumped 13-fold to its all-time-high around $20,000

It’s important to note that as Wall Street celebrated its best full-year performance for stock investors in six years, with the S&P 500 posting a 29% price gain, bitcoin’s performance was roughly triple in size

Adam: Looking out to 2020, it’s going to be a landmark year for crypto development along with a lot of other major world events such as the U.S. presidential election and the quadrennial summer olympics in Tokyo

Perhaps the most high-profile event in the crypto space is bitcoin’s so-called halving, expected in May, when the supply of new units of the cryptocurrency will be cut in half

Some analysts have predicted that the reduction in bitcoin supply, at a time when investor demand for cryptocurrency is increasing, could drive the price to a new all-time high around $100,000

Though other analysts say they think that traders and cryptocurrency miners have already adjusted their price models to reflect anticipated reduction in new bitcoin supply, which means that the impact of the halving should already be theoretically be baked into the market

Brad: Nic Carter of Castle Island Ventures wrote last week in a post on The Block that he thinks that the crypto industry is really just about halfway through a deleveraging from the bubble levels we saw in 2017

He thinks we’ll see further rationalization in the industry in 2020, with some token projects failing to achieve anything resembling critical mass, and dying off, especially in the face of continued regulatory scrutiny

And in yet another setback for a South Korean crypto exchange following last year’s alleged $49 million hack of the Upbit exchange, Bithumb has reportedly had about $70 million worth of taxes on cryptocurrency gains withheld, the first time the country’s tax agency has taken such a step

Bithumb reportedly plans to take legal action against the claim, leaving it unclear what the consequences might be for customers or the exchange itself

 A tax professor at the University of Seoul told CoinDesk that the exchange might have to make the tax payment and then go back and try to collect the amount from foreign clients, though from a practical standpoint, that might prove impossible

Adam: Turning to todays featured story, with several proposed central bank digital currencies (CBDCs) picking up steam, CoinDesk’s Danny Nelson reports on one projects quiet holiday launch…

The Bahamas’ digital currency pilot project went live late last month.Residents of the island can now enroll in the Central Bank of The Bahamas’ “Project Sand Dollar,” which began Dec. 27.

They’ll receive mobile wallets the Bahamian government sees as facilitating the future of payments on the island chain. Bankers said “Sand Dollar” is a “digital fiat currency” – not a cryptocurrency, stablecoin or competitor to the Bahamian dollar. Instead, it is simply a digital version “equivalent in every respect to the paper currency,” they said in the project outline

But it is also a step toward the Bahamas’ long-term goal of launching a fully-fledged central bank digital currency (CBDC), Also called the sand dollar. That larger project would link domestic residents and businesses across a seamless digital payment infrastructure.

CoinDesk.com

Pausing for a moment, we’ll turn to Dr. Gina Pieters, who recently wrote for CoinDesk’s year in review series:

The Central Bank consensus is that decentralization is not a desirable property in a CBDC as it could aid tax avoidance and enable criminal payment systems.

Therefore, while they recognize digital money may be an improvement over physical money, a central bank designed digital currency will not resemble a decentralized cryptocurrency.

Planned CBDCs are not bitcoin-but-issued-by-the-government. They are more like credit-cards-but-issued-by-the-government, where your transactions can be tracked, examined and linked to your taxpayer-identity. 

CoinDesk.com

There’s always been two, largely incompatible, ways to appreciate the revolutionary possibilities of cryptocurrency, blockchains and tokens as a way to track ownership as a whole.  Call it the difference between innovation and optimization. Innovators like cryptocurrency because its radical trust model eliminates the power which traditional systems imbue in central banks or other forms of monetary policy.  They see the current system as fatally flawed by short term human bias, among other things, and decentralized cryptocurrency with its currency issuance publicly known a hundred years in advance, presents what looks like unstoppable competition in a space where competition is simply not allowed, yet is so desperately needed. 

The move towards Central Bank Digital Currencies (CBDCs) is the optimization perspective – These people broadly think that current central bank operated money systems are great, but could certainly benefit from improvements… And that’s what they see this technology as, optimizing or improving the rough edges on a system which is already great, and which they have no desire to fundamentally change.

Returning to Danny for more details on the Bahamian program:

In this vision, residents can pay retailers through wallet-linked QR codes, with banks moving funds in digital form. The Central Bank believes this could ultimately cut currency printing costs and transaction fees while enhancing financial inclusion.

“A widely adopted CBDC would place users at less risk of violent crimes that target holders of cash, and potentially reduce security and insurance costs associated with keeping cash on business premises,” according to the outline.

For now, however, the sand dollar faces far more restrictive limits from the government. Businesses cannot hold more than B$1 million in their digital wallets, nor can they transact more than one-eighth of their annual business through the wallets in any given month. And individuals max out at B$500, with higher limits coming through “enhanced due diligence” on their accounts.

CoinDesk.com

Adam: We’ll have more on this developing story as events unfold.

Adam: And now, for today’s spotlight, we’re stepping outside the crypto space to take a look at global foreign exchange markets, and specifically the U.S. dollar’s status as the world’s dominant currency

Brad: The U.S. dollar has been the primary currency for payments in international trade for almost a century, since the world wars of the first half of the 1900s, when the British empire’s influence faded and its currency, pound sterling, saw its use as a global tender decline

Of course the dollar also occupies a key spot in discussion of cryptocurrencies, since the original and oldest digital asset, bitcoin, was originally proposed as a private-market alternative to government-issued currencies like the dollar in peer-to-peer payments

But based on the way that crypto markets have evolved, the dollar is impossible to avoid, since bitcoin is priced in dollars, similar to the way major commodities like oil and gold are quoted in dollars

there’s a growing roster of so-called stablecoins like tether, USD Coin and dai, whose value is pegged to the dollar

And in some ways, even China’s planned digital version of its renminbi might trade a lot like a dollar-linked cryptocurrency, since Chinese authorities typically synch the renminbi’s daily fixed exchange rate with wherever the dollar happens to be trading    

Now the big question is how long the dollar can hold on as the global reserve currency

It’s an important question because there are big benefits to the U.S. from having its own currency as such a pillar of global capital markets, but also there’s a self-perpetuating cycle at work here that creates imbalances and the risks of rapid and messy change 

U.S. consumers benefit disproportionately from the dollar’s strength, since foreigners are essentially subsidizing Americans’ habit of importing more than they export 

And global demand for dollar-denominated assets helps keep interest rates low on things like Treasury bonds despite a U.S. federal budget deficit of more than $1 trillion a year

That dynamic encourages governments, businesses and households to take on ever-growing amounts of debt, which might be difficult to pay back if borrowing costs suddenly jumped

History shows that these epochal shifts do eventually come, but change can be quite slow in coming

And a new report this week from CoinDesk showed that, as China’s global ambitions and rapidly advancing digital-asset technologies pose new threats to the dollar, the U.S. currency looks as strong as ever in global capital markets

As of Dec. 30, an index of the U.S. dollar’s value is up 24 percent over the past decade

That happened even as the Federal Reserve pumped more than $2 trillion of freshly printed money into the financial system and U.S. national debt more than doubled to about $23 trillion – both developments that economists have warned could faster inflation and a reduction in the dollar’s purchasing power 

And the greenback’s share of central bank foreign exchange reserves stands at about 62 percent, essentially unchanged since Jan. 1, 2010, according to the International Monetary Fund

The second-place euro, touted by some leading economists in the late 2000s as a potential rival to the dollar, saw its share of central bank reserves decline over the past decade to about 20 percent from 26 percent

The Japanese yen, seen as a threat to the dollar in the 1980s, now accounts for just 5.4 percent of central bank reserves

The British pound, which as we said earlier dominated global trade in the 1800s, has a modest share of 4.4 percent, with its future uncertain as the U.K. moves toward an exit from the European Union

And China, despite decades of rapid economic growth and a push by authorities there to expand the renminbi’s use in international trade and payments, has never seen its currency account for more than 2 percent of central banks’ reserves.

As for digital assets, frequently touted as the future of money, they barely register as an asset class compared with government-issued currencies

Bitcoin’s entire market value stands at about $133 billion, well below central banks’ de minimis $218 billion allocation to the renminbi

The point here is that as the new decade of the 2020s dawn, and we see an array of what appear to be very serious challenges to the dollar’s dominance on the horizon, the dollar is going to be tough to dethrone

And if the dollar were to lose its dominant status, it would entail a pretty landmark and potentially tumultuous shift not just in global capital markets but also in the geopolitical landscape 

Categories
Resource Stocks

Pistol Bay drops Pakwash South project

Pistol Bay drops Pakwash South project
The Pakwash South property is located southeast of the Dixie Lake gold project, pictured here. (Image courtesy of Great Bear Resources).

The Pakwash South property is located southeast of the Dixie Lake gold project, pictured here. (Image courtesy of Great Bear Resources).

Pistol Bay Mining (TSX.V: PST) announced that it will not be proceeding with the 100% option on the Pakwash South property in Ontario.

The project, located near Red Lake, comprises 2,130 hectares and lies southeast of the Dixie Lake gold discovery now being explored by Great Bear Resources.

In a media statement, Charles Desjardins, Pistol Bay’s president and CEO, said that the company decided to drop the project in order to focus its efforts on the Pakwash North and Pakwash East properties, both located in the vicinity of a recent Great Bear Resources discovery.

Desjardins explained that the Pakwash East block comprises of 35 cells, with an area of approximately 716 hectares. It is 12.5 kilometres southeast of Great Bear Resources’ Dixie property and adjoins a 9,650-hectare claim group registered to Great Bear Resources.  

The Pakwash North block, on the other hand, is located 44 kilometres southeast of Red Lake, comprises 106-cells, occupies 2,174 hectares and lies 21 kilometres southeast of the Dixie Lake gold discovery.

Categories
Pharma Stocks

Melinta files for bankruptcy in another dark day for antibiotics

by Nick Paul Taylor

Melinta’s filing for bankruptcy capped off a bleak year for the antibiotic industry. (Getty/Gam1983)

Melinta Therapeutics has filed for Chapter 11 bankruptcy. Deerfield is set to take control of Melinta as payment for the $140 million loan it extended to the antibiotics business.

New Jersey-based Melinta sounded the alarm repeatedly in 2019, warning investors of doubts about its ability to continue as a going concern in May and stating in November that the situation was likely to come to a head in the next few months. Faced with a bleak financial situation, Melinta has put together a restructuring agreement designed to put it on sounder fiscal footing. 

The agreement will see Deerfield receive 100% of the equity issued by the reorganized company. To facilitate the agreement, Melinta is seeking Chapter 11 protection. Melinta is set to lay off about 60 people in conjunction with the reorganization. 

Earlier efforts by Melinta to improve its financial performance also cost people their jobs but failed to keep the company out of bankruptcy. Jennifer Sanfilippo, the latest in a succession of people to hold the CEO title at Melinta, thinks this time will be different. 

“We are confident that this process will secure new ownership of the business with the financial resources to support the company’s antibiotics portfolio and ensure these potentially life-saving products continue to get to patients in need,” Sanfilippo, Melinta’s interim CEO, said in a statement. 

Melinta’s filing for bankruptcy capped off a bleak year for the antibiotics industry. Aradigm and Achaogen filed for bankruptcy in the first half of the year, despite the latter company winning FDA approval for an antibiotic in June 2018.

That series of bankruptcy filings, which featured two companies with commercial products, will add to fears that the antibiotics business model is broken. Some investors and biotechs retain an interest in the sector—Brii Biosciences, for example, is spending some of its $260 million fundraising haul on antibiotics R&D—but other therapeutic areas have a far better track record of delivering a return on investment. 

Categories
Cannabis

Global Cannabis Stocks Close Out Challenging Year with 1.1% Gain in December

Exclusive article by Alan Brochstein, CFA

After beginning the year with a 57.4% gain in Q1 and then dropping for eight consecutive months, the Global Cannabis Stock Index ended December with a big jump that enabled the index to gain 1.1% for the month, closing at 42.20:

The index, which had 44 qualifying members during the month following the quarterly rebalancing at the end of September, declined 54.9% in 2018 and lost 34.1% in 2019:

The decline left the index at levels not seen in over three years, down almost 77% from its early 2018 closing high at 180.02 but up 9.3% from its closing low on December 18th at 38.62:

5 names gained more than 20% during December:

Origin House’s strength was driven by the rally in Cresco Labs, with which it is merging in January in an all-stock deal, compounded by a narrowing of the discount to the price implied by the transaction based upon the price of Cresco Labs from 16% to just over 5%.  Sundial, which conducted its IPO at $13 during the summer, bounced off of a post-IPO low set in early December at $1.88. Cresco Labs rallied ahead of legalization in Illinois and its pending acquisition of Origin House. The company also raised $50 million in an additional sale/leaseback transaction announced during the month. Harvest Health & Recreation surged in the final days of the month after it priced a large debt offering. Planet 13 was a top performer for the second consecutive month.

5 names fell by more than 20% during December:

Elixinol’s weakness was due to competitive pressures in the industry as well as the resignation of its founder, Paul Benhaim, who had recently moved into the role of Chief Innovation Officer after having served as CEO. HEXO crushed its stock with a capital raise the day after Christmas that was significantly below the prior closing price. Emerald Health also suffered from a capital raise that pressured its stock along with ongoing concerns regarding its cannabis joint venture, Pure Sunfarms. Charlotte’s Web and CV Sciences, like Elixinol, continued to see pressure on their stocks after a slowdown in growth for the companies and the overall CBD sector became apparent in November during the financial reporting season.

We have also published separate reviews of the performance of the Canadian LP Index and the American Cannabis Operators Index:

Using data from 12/20, we have rebalanced the index, effective as of 12/31. As a result of lower trading volumes, we have slightly reduced the minimum average daily value traded from $800K to $500K, our first change in more than a year. The number of names in the index in January will be 41, as we have removed nine names and added six new ones. Departing the index due to no longer meeting price or volume criteria are Canopy Rivers (TSX:  RIV) (OTC: CNPOF), Elixnol Global (ASX: EXL) (OTC: ELLXF), Emerald Health (TSXV: EMH) (OTC: EMHTF), Fire & Flower (TSX: FAF) (OTC: FFLWF), Flowr (TSXV: FLWR) (OTC: FLWPF), Khiron (TSXV: KHRN) (OTC: KHRNF), Namaste Technologies (TSXV: N) (OTC: NXTTF) and PharmaCielo (TSXV: PLCO) (OTC: PCLOF). We have also removed Origin House (CSE: OH) (OTC: ORHOF) ahead of its pending acquisition by Cresco Labs (CSE: CL) (OTC: CRLBF).

Joining the index are Akerna (NASDAQ: KERN), Green Growth Brands (CSE: GGB) (OTC: GGBXF), GrowGeneration (NASDAQ: GRWG), Liberty Health Sciences (CSE: LHS) (OTC: LHSIF), TerrAscend (CSE: TER) (OTC: TRSSF) and Vireo Health (CSE: VREO) (OTC: VREOF).

We will summarize the index performance again in a month. You can learn more about the index members and the qualifications for inclusion by visiting the Global Cannabis Stock Index. A more complete analysis of the index is available at 420Investor.com. Be sure to bookmark the page to stay current on cannabis stock price movements within the day or from day-to-day.

New Cannabis Ventures maintains six proprietary indices designed to help investors monitor the publicly-traded cannabis stocks, including the Global Cannabis Stock Index as well as the Canadian Cannabis LP Index and its three sub-indices. The sixth index, the American Cannabis Operator Index, was launched at the end of October last year and tracks the leading cultivators, processors and retailers of cannabis in the United States.

Categories
Pharma Stocks

An immuno-oncology triplet from Roche shows promise in mouse models of several tumors

by Arlene Weintraub

Stabilizing blood vessels surrounding tumors improved responses to CD40-targeted drugs in mouse models of several cancers. (Alexandra/München)

CD40, a receptor on the surface of immune cells, has long been of interest in oncology research because activating it stimulates cancer-killing T cells. Several companies have developed antibody drugs targeting CD40, including Roche, but they’ve proven disappointing on their own in clinical trials.

Scientists at the University of Basel say they may have found a way to improve responses to CD40 antibodies. They combined a CD40 drug with two other antibodies that are anti-angiogenic, meaning they plug up leaky blood vessels that feed tumors. The combination accelerated tumor destruction in mouse models of several cancers, including breast, colon and skin cancers, they reported in the journal Proceedings of the National Academy of Sciences.

“Normally, the blood vessels of a tumor are leaky or stunted. Therefore, there is no good way for killer T-cells to get inside,” explained lead author Abhishek Kashyap of the University of Basel in a statement.

Kashyap’s team collaborated with scientists at the Roche Innovation Center to test three of the company’s drugs in combination. They were Avastin, Roche’s blockbuster anti-angiogenic cancer treatment that blocks VEGF, and two experimental drugs: one targeting another anti-angiogenic molecule, Ang2, and the second aimed at CD40.

The two anti-angiogenic drugs stabilized the blood vessels surrounding the tumors, improving the flow of killer cells that attacked the cancer, the researchers reported. But the triplet also seemed to turn “cold” tumors “hot,” meaning the drugs changed the microenvironment in a way that made the cancer more vulnerable to immunotherapy.

RELATED: AACR: Apexigen, BMS steal the show with promising I-O combo in pancreatic cancer

Several clinical trials investigating the potential of CD40 combination treatments are already underway. Apexigen’s APX005M combined with chemotherapy and Bristol-Myers Squibb’s anti-PD1 blockbuster Opdivo has shown promise in early clinical trials in pancreatic cancer, for example. Apexigen is also testing a combination of APX005M, Opdivo and cabiralizumab, an anti-CSF-1 antibody that BMS and Five Prime Therapeutics are developing.

Roche is testing its CD40 drug, selicrelumab, with its anti-PD-L1 drug Tecentriq in solid tumors. It’s also investigating combining selicrelumab with either Avastin or vanucizumab, a bispecific antibody that targets both VEGF-A and Ang2.

The new study led by the University of Basel concluded that the key to targeting CD40 successfully in cancer “is likely to be realized in combination with other, nonredundant immune modulators,” the researchers wrote. “We consider our findings useful in the light of current early-phase clinical studies that investigate agonistic anti-CD40 antibodies in combination with various antiangiogenic agents.”

Categories
Cannabis

Cresco Labs Makes History on January 1st With First Sale of Adult-Use Cannabis in Illinois at Its Sunnyside* Lakeview Dispensary

Company Served 3,145 Recreational Customers on First Day

Sunnyside* Customer Jacqueline Ryan Makes the First Legal Purchase of Recreational Cannabis in Illinois at the Company’s Lakeview Dispensary (Photo: Business Wire)

CHICAGO, January 2, 2020–(BUSINESS WIRE)–Cresco Labs (CSE:CL) (OTC:CRLBF) (“Cresco” or “the Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced today that the Company served 3,145 people on New Year’s Day at its five Sunnyside* Dispensaries located in Lakeview, Elmwood Park, Champaign, Buffalo Grove and Rockford, Illinois. Sunnyside* also sold 9,258 cannabis products, including Cresco’s house of brands and items from other Illinois suppliers, with an average ticket price totaling $135.

Customers began to form lines outside Sunnyside* locations as early as 8 PM on New Year’s Eve, and lines wrapped around the buildings throughout the day as recreational customers showed their excitement to be part of this historic day. The dispensaries opened at 6 AM to immediately start serving recreational customers, with the first sale in the state of Illinois taking place shortly thereafter at Sunnyside* Lakeview. Jacqueline Ryan from Forest Park was the first customer to purchase adult-use cannabis, followed by siblings Elise and Aaron Swopes, two participants in Cresco’s Chicago incubator program, which is part of the Company’s SEED (Social Equity and Educational Development) initiative, and Illinois Lt. Gov. Juliana Stratton, who played a critical role in shaping the state’s cannabis legislation.

We’re ecstatic for our Sunnyside* dispensaries to begin serving recreational customers on such a historic day that launches a new era of cannabis and the development of an industry that will bring greater justice, social equity and business ownership opportunities throughout the state.

Charlie Bachtell, Cresco Labs CEO and
Co-founder

With 13 million residents and 100 million annual tourists, Illinois is predicted to be one of the largest recreational cannabis markets in the United States. Cresco is uniquely positioned in the supply-constrained state, with permission for the largest cultivation footprint at 630,000 square feet and ten retail dispensaries, including three in high traffic areas in the city of Chicago.

Joe Caltabiano, Cresco Labs President and Co-founder, added, “We’re thrilled to be part of this historic day and to witness firsthand so much excitement from people on the first day of legal cannabis sales. Our dispensaries served thousands of customers on day one by educating new cannabis consumers, making product recommendations and making sure they had a seamless shopping experience. With five newly re-concepted Sunnyside* locations and an additional five dispensaries opening soon in high profile locations such as one next to Wrigley Field and two in Chicago’s downtown Central District, we expect to serve thousands more customers in response to strong demand. Our Sunnyside* concept is designed to move traffic efficiently, so despite the fact that long lines will likely continue in the first few days of adult-use legalization, we are positioned to ensure that each of our customers gets only the best possible service and the products they are looking for. Cresco is already the leader in Illinois, and we expect to be able to maintain this leadership position as the recreational cannabis market grows, contributing solidly to our overall revenue and our profitability.”

Media Press Kit:

  • Sunnyside Lakeview Jan. 1 Adult-Use Cannabis First Sale in IL Photography:
  • Sunnyside Lakeview Jan. 1 Adult-Use Cannabis First Sale in IL Video Footage:
  • Cresco Labs—Cannabis Industry Broll:

About Cresco Labs:

Cresco Labs is one of the largest vertically-integrated multi-state cannabis operators in the United States. Cresco is built to become the most important company in the cannabis industry by combining the most strategic geographic footprint with one of the leading distribution platforms in North America. Employing a consumer-packaged goods (“CPG”) approach to cannabis, Cresco’s house of brands is designed to meet the needs of all consumer segments and includes some of the most recognized and trusted national brands including Cresco, Remedi and Mindy’s, a line of edibles created by James Beard Award-winning chef Mindy Segal. Sunnyside*, Cresco’s national dispensary brand, is a wellness-focused retailer designed to build trust, education and convenience for both existing and new cannabis consumers. Recognizing that the cannabis industry is poised to become one of the leading job creators in the country, Cresco has launched the industry’s first national comprehensive Social Equity and Educational Development (SEED) initiative designed to ensure that all members of society have the skills, knowledge and opportunity to work in and own businesses in the cannabis industry. Learn more about Cresco Labs at www.crescolabs.com.

Original press release